SEC Form 4 · accession 0001662252-17-000232
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Firdaus J. Dastoor
Director
Period of report
Nov 15, 2017
Accepted (ET)
Nov 17, 2017 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $2.18 | Nov 15, 2017 | A | 25,000 | A | — | Nov 15, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1On November 15, 2017 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on November 15, 2017 of $2.18. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date.